Stock Events

Stock Events

Genprex 

$1.3
100
-$0.16-10.96% Today

Statistics

Day High
1.34
Day Low
1.28
52W High
-
52W Low
-
Volume
4,663
Avg. Volume
-
Mkt Cap
2.95M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-13
-12.83
-12.67
-12.5
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-42.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GNPX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. has a broad portfolio of cancer therapies, including gene therapies, making it a major competitor in the oncology market.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics, Inc. focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the same innovative treatment space as Genprex.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics AG is a leader in gene editing technology, which can be applied to cancer treatment, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a cutting-edge technology for treating genetic diseases and cancer, competing with Genprex's gene therapy approach.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine, Inc. works on gene editing technologies, including CRISPR, for the treatment of serious diseases, offering an alternative to Genprex's therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals, Inc. focuses on RNAi (RNA interference) therapeutics for the treatment of genetic diseases, indirectly competing with Genprex's gene therapy approach by offering a different method of genetic intervention.

About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Show more...
CEO
ISIN
US3724463027

Listings

LSE
GB
0A8I.LSE
F
DE
2DE.F
XNAS
US
GNPX
BOATS
BOATS
GNPX.BOATS

0 Comments

Share your thoughts

FAQ

What is Genprex stock price today?▼
The current price of GNPX.BOATS is $1.3 USD — it has decreased by -10.96% in the past 24 hours. Watch Genprex stock price performance more closely on the chart.
What is Genprex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genprex stocks are traded under the ticker GNPX.BOATS.
What is Genprex market cap?▼
Today Genprex has the market capitalization of 2.95M
When is the next Genprex earnings date?▼
Genprex is going to release the next earnings report on June 03, 2026.
What is Genprex revenue for the last year?▼
Genprex revenue for the last year amounts to 0 USD.
What is Genprex net income for the last year?▼
GNPX.BOATS net income for the last year is -42.78M USD.
When did Genprex complete a stock split?▼
Genprex has not had any recent stock splits.